The company J. Craig Venter founded in 1998 to challenge the Human Genome Project ran a data center with 70 terabytes of storage. Venter's latest scheme--creating the world's largest sequencing center--will fill that in less than one week.
Watch out, Google. Genome pioneer Craig Venter, well known for elbowing his way to the front of a scientific race, is launching a new company that will tackle the multitude of diseases that affect aging.
Over the past year Google has increasingly extended its tendrils into healthcare, with the creation of Calico and development of smart contact lenses following on from earlier investments in DNAnexus and 23andMe.
George Washington University and the National Institutes of Health this week took high-speed Internet connections to the next level. The organizations are using their new 100-Gbps links to the Internet2 Network to trial 40-Gbps transfers of genomics data.
It is months since the chatter around Chinese sequencing giant BGI's initial public offering advanced from "will it happen?" to "when, where and how much?" Now Bloomberg has some answers. A $400 million IPO in Hong Kong is reportedly penciled in for the fourth quarter.
As the cost of sequencing a whole human genome has edged downward toward the fabled $1,000 mark, some observers have become increasingly concerned about how much time and money it will take to analyze the data. To clear the potential bottleneck, U.S. researchers have applied a supercomputer to the task.
Tech startup incubator Y Combinator has a reputation as a spawning ground for major companies, with Dropbox and Airbnb among those passing through its program. Yuri Milner played a role in the accelerator in recent years, but reduced his commitment in December. Now, he has revealed that some of the cash and time this freed up will go into running a genomics incubator with Illumina.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
The British government has been unveiling a series of genomics and bioinformatics initiatives intended to revive its ailing biopharma industry. This week brought news of $52 million in funding for 5 bioinformatics projects run by British research institutes.
One in three people in the U.S. either already have or are at high risk of developing diabetes, and analyzing genetic data for answers about how best to treat these patients is a daunting task. Now a collection of Big Pharma companies are teaming up to share the burden.